Daniel S. Chen, MD, PhD, is a Director on the Society for ImmunoTherapy of Cancer (SITC) Board of Directors, the former Chief Medical Officer for IGM Biosciences, and former Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche. He is a reviewer for Nature, Immunity and Clinical Cancer Research, serves on the Board of Directors for SITC, gave the keynote presentation at the AACR NCI EORTC Annual Meeting 2014 and presented at the US Congressional Briefing on Immuno Oncology in 2017. He has continued to publish with academic and industry collaborators in the field of cancer immunotherapy, including the often-referenced Chen and Mellman manuscripts, “Oncology meets Immunology: the Cancer-Immunity Cycle,” “Elements of cancer immunity and the cancer-immune set point” and the Hegde and Chen manuscript “Top 10 Challenges in Cancer Immunotherapy.”
Dr. Roybal is an Associate Professor in the Department of Microbiology and Immunology at the UCSF. He is a member of the Parker Institute for Cancer Immunotherapy and an inaugural Chan Zuckerberg Biohub Investigator. He was recently awarded the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy and the NIH New Innovator Award. The Roybal lab harnesses the tools of synthetic biology to engineer to control and enhance engineered immune cell therapies. His body of work was foundational to the next-generation immune cell therapy company, Cell Design Labs, where he was a founding scientist (now part of Gilead). He was also instrumental in developing universal CAR T cell technology in collaboration with Xyphos Biosciences (now part of Astellas). He has recently co-founded Arsenal Biosciences, which focuses on building cellular therapies for solid tumors with a combination of cutting-edge synthetic biology and gene editing technologies.
Development of NextGen Cellular Therapeutics with Synthetic Biology
Engineered immune cell therapies for cancer suffer from life-threatening toxicities or inefficacy depending on the clinical indication. I will provide an overview of our synthetic biology toolkit that allows for the control and customization of immune cell responses to improve the safety and efficacy of cell-based therapies.
Work by Dr. Sonja Schrepfer is at the forefront of stem immunobiology and paves the way for treatment of a wide range of diseases – from supporting functional recovery of failing myocardium to the derivation of other cell types to treat diabetes, blindness, cancer, lung, neurodegenerative, and related diseases. Her work demonstrates that protecting transplanted cells from immune rejection is the key to unlocking the potential of regenerative medicine. Dr. Schrepfer is Professor at the University of California San Francisco (UCSF), Gladstone-UCSF Institute of Genomic Immunology, and a Scientific Founder and SVP (Head of the Hypoimmune Platform) of Sana Biotechnology, Inc.
Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Prof. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California. From 2002-2017, he led research and preclinical development at Genmab, leading to seven product approvals to date. He is an inventor of ofatumumab (Arzerra, 2009; KESIMPTA, 2020), daratumumab (DARZALEX, 2015, DARZALEX-Faspro, 2021), teprotumumab (Tepezza, 2020), amivantamab (RYBREVANT, 2021), tisotumab vedotin (Tivdak, 2021) and two clinically translated technologies to generate bispecific (DuoBody) and effector-function enhanced (HexaBody) antibodies. In 2015, he became a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. In 2018, he joined LAVA Therapeutics, a biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform cancer therapy, as its Executive Vice President and Head of R&D.
Bispecific Gamma-delta T Cell Engagers
LAVA is developing a bispecific antibody γδ T cell engager (bsTCEs) platform that leverages the unique qualities of γ9δ2 effector T cells. LAVA’s bsTCEs were selected to create a wide therapeutic window with high activity against tumor cells whilst leaving healthy cells unharmed. LAVA progressed two bsTCEs to the clinic, one in haematological cancer and one in oncology.